首页 | 本学科首页   官方微博 | 高级检索  
     


Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy
Authors:J.-P. Menard   J.-M. Extra   J. Jacquemier   M. Buttarelli   E. Lambaudie   M. Bannier   I. Brenot Rossi  G. Houvenaeghel  
Affiliation:1. Department of Surgery, Institut Paoli-Calmettes, Regional Cancer Center, 232 Bvd, Sainte Margueritte, 13273 Marseille Cedex 9, France;2. Department of Medical Oncology, Institut Paoli-Calmettes, Regional Cancer Center, 232 Bvd, Sainte Margueritte, 13273 Marseille Cedex 9, France;3. Department of Pathology, Institut Paoli-Calmettes, Regional Cancer Center, 232 Bvd, Sainte Margueritte, 13273 Marseille Cedex 9, France;4. Department of Nuclear Medicine, Institut Paoli-Calmettes, Regional Cancer Center, 232 Bvd, Sainte Margueritte, 13273 Marseille Cedex 9, France
Abstract:

Background

Several authors reported sentinel lymph node biopsy (SLNB) after neoadjuvant chemotherapy (NC). Nevertheless, the ideal time of SLNB is still a matter of debate.

Methods

We evaluated the feasibility and the accuracy of SLNB before NC using a combined procedure (blue dye and radio-labelled detection) before NC. Axillary lymph node dissection (ALND) was performed after completion of NC in a homogeneous cohort study with clinically axillary node-negative breast cancer.

Results

Among the 20 women who had metastatic SLNB (65%), 4 (20%) had additional metastatic node on ALND. By contrast, all the 11 women who had no metastatic SLNB had no involved nodes in the ALND. The SLN identification rate before NC was 100% with any false negative.

Conclusions

SLNB before NC is a feasible and an accurate diagnostic tool to predict the pre-therapeutic axilla status. These findings suggest that ALND may be avoided in patients with a negative SLNB performed before NC.
Keywords:Sentinel node   Neoadjuvant chemotherapy   Breast cancer
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号